Share the post "Bacil Pharma ‘s Q1 Update: Profit Falls by 250% Year-on-Year"
Highlights
- The presented financial data is Standalone to provide a comprehensive overview of the company performance.
- Income over the Year and quarter: There has been decline in other income over the past year which is -77.08 %, Marginal decrease of -47.62% in other income during this quarter.
- Profit over the Year and quarter: Challenges in sustaining profitability for Bacil Pharma Ltd.. Profit dropped by -300 % Year to Year, Bacil Pharma Ltd.’s profitability dropped by -17.07 % Quarter to Quarter.
- EPS over the Year and quarter: EPS declined by -300.00 % Year to Year. EPS decreased by -14.29 % in previous quarter. Analysis needed for shareholder value.
| Metrics | Previous Year | Previous Quarter | Current Quarter | Quarter to Quarter Difference | Year to Year Difference |
|---|---|---|---|---|---|
| Sales | Rs. 0 Cr | Rs. 0 Cr | Rs. 0 Cr | 0 % | 0 % |
| Expenses | Rs. 0.03 Cr | Rs. 0.06 Cr | Rs. 0.05 Cr | -16.67 % | + 66.67 % |
| Operating Profit | Rs. -0.03 Cr | Rs. -0.06 Cr | Rs. -0.05 Cr | + 16.67 % | -66.67 % |
| OPM % | 0 % | 0 % | 0 % | 0 % | 0 % |
| Other Income | Rs. 0.048 Cr | Rs. 0.021 Cr | Rs. 0.011 Cr | -47.62 % | -77.08 % |
| Interest | Rs. 0 Cr | Rs. 0 Cr | Rs. 0 Cr | 0 % | 0 % |
| Depreciation | Rs. 0 Cr | Rs. 0 Cr | Rs. 0 Cr | 0 % | 0 % |
| Profit before tax | Rs. 0.02 Cr | Rs. -0.04 Cr | Rs. -0.04 Cr | + 0 % | -300 % |
| Tax % | 0 % | -0 % | -0 % | 0 % | 0 % |
| Net Profit | Rs. 0.02 Cr | Rs. -0.04 Cr | Rs. -0.03 Cr | + 25 % | -250 % |
| EPS in Rs | Rs. 0.03 | Rs. -0.07 | Rs. -0.06 | + 14.29 % | -300 % |
Today, we’re looking at Bacil Pharma Ltd.’s financial performance for the Q1(Jun 2024).Expenses decreased slightly by -16.67 % quarter-on-quarter, aligning with the annual rise of 66.67 %. Operating profit, while down -66.67 % compared to last year, faced a quarter-on-quarter increase of 16.67 %, signaling a short-term expansion in margins.
Other income fell by -47.62 % compared to the last quarter, despite an annual decline of -77.08 %. Profit before tax declined annually by -300 % but saw an increase from the preceding quarter by 0 %.
Net profit fell by -250 % year-on-year but experienced a 25 % expansion from the last quarter. And finally, Earnings Per Share (EPS) displayed an annual downturn of -300 % but a quarterly rise of 14.29 %. In summary, Bacil Pharma Ltd.’s annual performance indicates steady growth, although the quarter-on-quarter figures suggest some areas may require strategic attention.
| Metrics | Previous Year | Previous Quarter | Current Quarter | Quarter to Quarter Difference | Year to Year Difference |
|---|---|---|---|---|---|
| Sales | Rs. 0 Cr | Rs. 0 Cr | Rs. 0 Cr | 0 % | 0 % |
| Expenses | Rs. 0.03 Cr | Rs. 0.06 Cr | Rs. 0.05 Cr | -16.67 % | + 66.67 % |
| Operating Profit | Rs. -0.03 Cr | Rs. -0.06 Cr | Rs. -0.05 Cr | + 16.67 % | -66.67 % |
| Net Profit | Rs. 0.02 Cr | Rs. -0.04 Cr | Rs. -0.03 Cr | + 25 % | -250 % |
| EPS in Rs | Rs. 0.03 | Rs. -0.07 | Rs. -0.06 | + 14.29 % | -300 % |
In reviewing Bacil Pharma Ltd.’s 2024(Q1) financial snapshot, key trends emerge, shedding light on the company’s performance.Expenses rose by 66.67 % compared to the previous year, with a decrease of -16.67 % quarter-on-quarter. Operating Profit dropped by -66.67 % annually, and saw a 16.67 % increase from the last quarter.
Net Profit showed yearly decrease of -250 %, and experienced a 25 % increase from the previous quarter. Earnings Per Share (EPS) fell by -300 % annually, however rose by 14.29 % compared to the last quarter. In essence, while Bacil Pharma Ltd. faces strong annual decline indicators, short-term improvements suggest the potential for recovery and the importance of strategic adjustments to counter market challenges effectively. That’s all for now in the financial sector.
[my_shortcode1]
![[fetch_key]](https://stocktradeupdates.com/wp-content/uploads/new_logos/SPICEISLIN.png)